Novo Nordisk Previews 44 EASD 2026 Abstracts: Wegovy Pill Real-World OCTANE Data, CagriSema, and Zenagamtide for the September 28-October 2 Milan Meeting
Novo Nordisk said on Wednesday, September 16, 2026 that it will present 44 abstracts at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2. The OCTANE study will report real-world data on Wegovy pill use, including weight outcomes, treatment switching, and patient-reported outcomes. Other presentations cover Wegovy 7.2 mg; CagriSema (cagrilintide plus semaglutide) data on appetite regulation, eating behavior, body composition, and bone remodeling from the REDEFINE and REIMAGINE programs; and zenagamtide, the unimolecular GLP-1 and amylin receptor agonist formerly called amycretin.